metricas
covid
Buscar en
Cirugía Española
Toda la web
Inicio Cirugía Española Cáncer de mama bilateral
Journal Information
Vol. 73. Issue 6.
Pages 347-350 (June 2003)
Share
Share
Download PDF
More article options
Vol. 73. Issue 6.
Pages 347-350 (June 2003)
Full text access
Cáncer de mama bilateral
Bilateral breast cancer
Visits
18624
José María del Val Gil1
Corresponding author
jval@hopl.insalud.es

Correspondencia: Dr. J.M. del Val Gil. Argentina 1, 6.° A. 44002 Teruel. España.
, Ana Cristina Utrillas Martínez, Francisco Javier Rebollo López, Manuel Francisco López Bañeres, Antonio Bermejo Zapatero, Manuel Sanz Gómez
Servicio de Cirugía General y del Aparato Digestivo. Hospital General de Teruel Obispo Polanco. Teruel. España.
This item has received
Article information
Resumen
Introducción

El cáncer de mama bilateral, o presencia de una neoplasia maligna, primaria e independiente, en cada mama, es una entidad afortunadamente menos frecuente que el unilateral, pero que debido a la mayor supervivencia de las mujeres con cáncer de mama, esa frecuencia va a aumentar de ahora en adelante.

Objetivo

Evaluación de los cánceres de mama bilaterales observados en nuestro servicio en los últimos años y compararlos con los unilaterales.

Material y métodos

Se realiza un estudio retrospectivo de 8 pacientes diagnosticadas e intervenidas quirúrgicamente de cáncer de mama bilateral de un total de 231 pacientes con cáncer de mama en nuestro servicio, lo que supone un 3,46%, entre los años 1995 y 1999, observando edad, sexo, intervalo de presentación, diagnóstico, estadio del segundo tumor, tratamiento realizado e influencia en el pronóstico.

Resultados

No ha habido ningún varón afectado de cáncer de mama bilateral. La edad media de presentación del segundo tumor es de 58 años, algo inferior a la del primer tumor (65,57 años); el estado posmenopáusico es el más frecuente, y el tumor la forma habitual de presentación. La mamografía en el seguimiento de las pacientes con cáncer de mama y la PAAF (punción-aspiración con aguja fina) han sido los pilares en el diagnóstico de la bilateralidad, con una media de 10 años de seguimiento (entre 1 y 30 años). La forma sincrónica sólo la hemos observado en un caso, y el intervalo entre el primer y el segundo tumor ha sido de 7 años de media (entre 1 y 20 años).

Conclusiones

El cáncer de mama bilateral es poco frecuente entre nuestras pacientes, predominando las formas metacrónicas sobre las sincrónicas, y no parece influir en el pronóstico final de las pacientes, sobre todo en lo referente a supervivencia.

Palabras clave:
Cáncer
Mama
Bilateral
Introduction

Bilateral breast cancer, which is the presence of a malignant, primary and independent neoplasm in each breast, is fortunately less frequent than unilateral breast cancer. However, because of greater survival in women with breast cancer, its frequency is due to increase.

Objective

To evaluate the bilateral breast neoplasms observed in our service in the last few years and to compare them with unilateral neoplasms.

Material and methods

Of a total of 231 patients with breast cancer in our service between 1995 and 1999, we retrospectively studied 8 patients (3.46%) with a diagnosis of bilateral breast cancer who underwent surgery. Age, sex, interval to presentation, diagnosis, staging of the second tumor, the treatment provided and influence on prognosis were analyzed.

Results

All patients with bilateral breast cancer were women. The mean age at presentation of the second tumor was 58 years, somewhat lower than that of the first tumor (65.57 years). Most women were postmenopausal and tumors were the most common form of presentation. Diagnosis of bilateral breast cancer was based on mammography during the follow- up of patients with breast cancer and fine-needle aspiration. The mean follow-up was 10 years (between 1 and 30 years). Only one case of synchronous breast cancer was observed and the mean interval between the first and second tumor was 7 years (between 1 and 20 years).

Conclusions

Bilateral breast cancer is infrequent among our patients. Metachronous forms are more common than synchronous forms and do not seem to influence patients’ final outcome, especially survival.

Key words:
Cancer
Breast
Bilateral
Full text is only aviable in PDF
Bibliografía
[1.]
L.H. McLean, J. Díaz Faes, F.B. Santillan, A. Willians, O. Bernabo.
Cáncer de mama bilateral.
pp. 243-254
[2.]
G.F. Robbins, S.W. Berg.
Bilateral primary breast cancer: a prospective clinico-pathological study.
Cancer, 17 (1964), pp. 1501-1527
[3.]
H.P. Leis.
Cáncer de mama bilateral.
pp. 833-841
[4.]
N.K. Raabe, T. Sauer, A. Erichsen, J.M. Nesland, S.D. Fossaa.
Breast cancer in the contralateral breast: incidence and histopathology after unilateral radical treatment of the first breast cancer.
Oncol Rep, 6 (1999), pp. 1001-1007
[5.]
R.S. Samant, I.A. Olivotto, J.S. Jackson, D. Mates.
Diagnosis of metachronous contralateral breast cancer.
Breast J, 7 (2001), pp. 405-410
[6.]
S. Mose, I.A. Adamietz, C. Thilmann, F. Saran, M. Bernhard, R. Pahnke, et al.
Bilateral breast carcinoma versus unilateral disease. Review of 498 patients.
Am J Clin Oncol, 20 (1997), pp. 541-545
[7.]
E.S. Hungness, M. Safa, E.A. Shaughnessy, B.S. Aron, P.A. Gazder, H.H. Hawkins, et al.
Bilateral synchronous breast cancer. Mode of detection and comparison of histologic features between the 2 breast.
Surgery, 128 (2000), pp. 702-707
[8.]
A.J. Donovan.
Cáncer mamario bilateral.
En: Clínicas Quirúrgicas de Norteamérica, Vol. 5. Editorial Interamericana, S.A, (1999), pp. 1151-1158
[9.]
L. Mariani, D. Coradini, E. Biganzoli, P. Boracchi, E. Marubini, S. Pilotti, et al.
Prognostic factors for metachronous contralateral breast cancer: a comparison of the linear Cox regression model and its artificial neural network extension.
Breast Cancer Res Treat, 44 (1997), pp. 167-178
[10.]
A. Gstafsson, P.I. Tartter, S.T. Brower, G. Lesnick.
Prognosis of patients with bilateral carcinoma of the breast.
J Am Coll Surg, 178 (1994), pp. 111-116
[11.]
L.A. Newman, A.A. Sahin, M.L. Bondy, N.Q. Mirza, G.S. Vlastos, G.J. Whitman, et al.
A case-control study of unilateral and bilateral breast carcinoma patients.
Cancer, 91 (2001), pp. 1845-1853
[12.]
P.P. Rosen, S. Groshen, D.W. Kinne, S. Hellmann.
Contralateral breast carcinoma: An assessment of risk and prognosis in stage I (T1N0M0) and stage II (T1N1M0) patients with 20 year follow-up.
Surgery, 106 (1989), pp. 904-910
[13.]
A. de la Rochefordiere, E. Mouret Fourme, B. Asselain, S.M. Scholl, F. Campana, P. Broet, A. Fourquet.
Metachronous contralateral breast cancer as first event of relapse.
Int J Radiat Oncol Biol Phys, 36 (1996), pp. 615-621
[14.]
M.A. Roubidoux, M.A. Helvie, N.E. Lai, C. Paramagul.
Bilateral breast cancer: early detection with mammography.
Radiology, 196 (1995), pp. 427-431
[15.]
L.A. Dawson, E. Chow, P.E. Goss.
Evolving perspectives in contralateral breast cancer.
Eur J Cancer, 34 (1998), pp. 2000-2009
[16.]
R. Kaas, A.A. Hart, A.P. Besnard, J.L. Peterse, E.J. Rutgers.
Impact of mammograpic interval on stage and survival after the diagnosis of contralateral breast cancer.
[17.]
K.M. Heaton, G.E. Peoples, S.E. Singletary, B.W. Feig, M.I. Ross, F.C. Ames, T.A. Uchholz, et al.
Feasibility of breast conservation therapy in metachronous or synchronous bilateral breast cancer.
Ann Surg Oncol, 6 (1999), pp. 102-108
[18.]
P. Broet, A. de la Rochefordiere, S.M. Scholl, A. Fourquet, V. Mosseri, J.C. Durand, et al.
Contralateral breast cancer: annual incidence and risk parameters.
J Clin Oncol, 13 (1995), pp. 1578-1583
[19.]
R. O’Regan, V.C. Jordan, W.J. Gradishar.
Tamoxifen and contralateral breast cancer.
J Am Coll Surg, 188 (1999), pp. 678-683
[20.]
C.L. Li, K.E. Malone, N.S. Weiss, J.R. Daling.
Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer.
J Natl Cancer Inst, 93 (2001), pp. 1008-1013
[21.]
L.A. Newman, H.M. Kuerer, K.K. Hung, G. Vlastos, F.C. Ames, M.I. Ross, et al.
Prophylactic mastectomy.
J Am Coll Surg, 191 (2000), pp. 322-330
[22.]
L.C. Hartmann, T.A. Sellers, D.J. Schaid, T.S. Frank, C.L. Soderberg, D.L. Sitta, et al.
Efficacy os bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.
J Natl Cancer Inst, 93 (2001), pp. 1633-1637
[23.]
J.S.Y. Lee, C.S. Grant, J.H. Donohue, T.B. Crotty, W.S. Harmsen, D.M. Ilstrup.
Arguments against routine contralateral mastectomy or undirected biopsy for invasive lobular breast cancer.
Surgery, 118 (1995), pp. 640-648
[24.]
T.J. Yeatman, G.H. Lyman, S.K. Smith, D.S. Reintgen, A.B. Cantor, C.E. Cox.
Bilaterality and recurrence rates for lobular breast cancer: considerations for treatment.
Ann Surg Oncol, 4 (1997), pp. 198-202
[25.]
H.S. Cody.
Routine contralateral breast biopsy: helpful or irrelevant? Experience in 871 patients, 1979-1993.
Ann Surg, 225 (1997), pp. 370-376
[26.]
J. Kollias, I.O. Ellis, C.W. Elston, R.W. Blamey.
Prognostic significance of synchronous and metachronous bilateral breast cancer.
World J Surg, 25 (2001), pp. 1117-1124
[27.]
P. Rebasa, H. Vallverdú, E. Lerma, M.C. Alonso, A. Gómez, J. Fuentes, et al.
Cáncer bilateral de mama. Revisión de las características clínicas e histológicas.
Cir Esp, 70 (2001), pp. 65-68
Copyright © 2003. Asociación Española de Cirujanos
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos